Multiple myeloma is a heterogeneous disease, and despite recent advances in therapeutic agents, several patients still relapse after therapy and have poor survival outcomes. The identification of high-risk features, including the presence of del(17p) and t(4;14), are crucial for improving diagnosis and outcomes for these patients. 

In this podcast, Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, and Meral Beksac, MD, Ankara University, Ankara, Turkey, hold a fascinating discussion on identifying high-risk myeloma patients, and parameters that can be used to define high-risk disease. The experts also comment on treatment strategies for this patient population, emphasizing the promise of CAR-T therapy and bispecific antibodies. This discussion took place at the 19th International Myeloma Society (IMS) Annual Meeting held in Los Angeles, CA.